WO2005105776A8 - Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both - Google Patents

Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both

Info

Publication number
WO2005105776A8
WO2005105776A8 PCT/EP2005/004479 EP2005004479W WO2005105776A8 WO 2005105776 A8 WO2005105776 A8 WO 2005105776A8 EP 2005004479 W EP2005004479 W EP 2005004479W WO 2005105776 A8 WO2005105776 A8 WO 2005105776A8
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compounds
benzodioxanes
arylsulfonyl
receptor
Prior art date
Application number
PCT/EP2005/004479
Other languages
French (fr)
Other versions
WO2005105776A1 (en
Inventor
Jacob Berger
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Jacob Berger
Shu-Hai Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA06012621A priority Critical patent/MXPA06012621A/en
Priority to NZ550441A priority patent/NZ550441A/en
Priority to CA002566196A priority patent/CA2566196A1/en
Priority to AU2005238179A priority patent/AU2005238179B2/en
Priority to AT05734404T priority patent/ATE458727T1/en
Priority to EP05734404A priority patent/EP1748995B1/en
Priority to JP2007511952A priority patent/JP2007536302A/en
Priority to BRPI0510642-7A priority patent/BRPI0510642A/en
Application filed by Hoffmann La Roche, Jacob Berger, Shu-Hai Zhao filed Critical Hoffmann La Roche
Priority to DE602005019562T priority patent/DE602005019562D1/en
Publication of WO2005105776A1 publication Critical patent/WO2005105776A1/en
Priority to IL178819A priority patent/IL178819A0/en
Priority to NO20065510A priority patent/NO20065510L/en
Publication of WO2005105776A8 publication Critical patent/WO2005105776A8/en
Priority to HK07109656.9A priority patent/HK1104533A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Compounds of the formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein m, n, p, Ar, X, R1, R2, R3, R4, R5 and R6 are as defined herein as well as compositions comprising these compounds and uses of the subject compounds for the preparation of medicaments for treating psychoses, schizophrenia, manic depressions, neurological disorders, memory disorders, attention deficit disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, food uptake disorders, Huntington's disease and gastrointestinal tract.
PCT/EP2005/004479 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both WO2005105776A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2007511952A JP2007536302A (en) 2004-05-05 2005-04-27 Arylsulfonylbenzodioxanes useful for modulating 5-HT6 receptor, 5-HT2A receptor, or both
CA002566196A CA2566196A1 (en) 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
AU2005238179A AU2005238179B2 (en) 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
AT05734404T ATE458727T1 (en) 2004-05-05 2005-04-27 ARYLSULFONYLBENZODIOXANES SUITABLE FOR MODULATION OF THE 5-HT6 RECEPTOR, THE 5-HT2A RECEPTOR OR BOTH RECEPTORS
EP05734404A EP1748995B1 (en) 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both
MXPA06012621A MXPA06012621A (en) 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both.
BRPI0510642-7A BRPI0510642A (en) 2004-05-05 2005-04-27 arylsulfonyl benzodioxanes useful for modulating 5-ht6 receptor, 5ht2a receptor or both
NZ550441A NZ550441A (en) 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
DE602005019562T DE602005019562D1 (en) 2004-05-05 2005-04-27 ARYLSULFONYLBENZODIOXANE SUITABLE FOR MODULATING THE 5-HT6 RECEPTOR, THE 5-HT2A RECEPTOR OR OTHER RECEPTORS
IL178819A IL178819A0 (en) 2004-05-05 2006-10-23 Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
NO20065510A NO20065510L (en) 2004-05-05 2006-11-29 Arylsulfonylbenzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor, or both.
HK07109656.9A HK1104533A1 (en) 2004-05-05 2007-09-05 Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5- ht2a receptor or both

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56831404P 2004-05-05 2004-05-05
US60/568,314 2004-05-05

Publications (2)

Publication Number Publication Date
WO2005105776A1 WO2005105776A1 (en) 2005-11-10
WO2005105776A8 true WO2005105776A8 (en) 2007-01-11

Family

ID=34965191

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004479 WO2005105776A1 (en) 2004-05-05 2005-04-27 Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both

Country Status (21)

Country Link
US (1) US7368567B2 (en)
EP (1) EP1748995B1 (en)
JP (1) JP2007536302A (en)
KR (1) KR100823805B1 (en)
CN (1) CN100540546C (en)
AR (1) AR048936A1 (en)
AT (1) ATE458727T1 (en)
AU (1) AU2005238179B2 (en)
BR (1) BRPI0510642A (en)
CA (1) CA2566196A1 (en)
DE (1) DE602005019562D1 (en)
ES (1) ES2338668T3 (en)
HK (1) HK1104533A1 (en)
IL (1) IL178819A0 (en)
MX (1) MXPA06012621A (en)
NO (1) NO20065510L (en)
NZ (1) NZ550441A (en)
RU (1) RU2372344C2 (en)
TW (1) TWI298636B (en)
WO (1) WO2005105776A1 (en)
ZA (1) ZA200608588B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2359725T3 (en) * 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISORDERS.
JP4738418B2 (en) * 2004-12-21 2011-08-03 エフ．ホフマン−ラ ロシュ アーゲー Chroman derivatives and their use in the treatment of CNS disorders
CN101218223A (en) * 2005-04-22 2008-07-09 惠氏公司 Benzodioxane and benzodioxolane derivatives and uses thereof
RU2008115032A (en) 2005-11-03 2009-12-10 Ф. Хоффманн-Ля Рош Аг (Ch) ARILSULFONILCHROMANES AS 5-NT6 INHIBITORS
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
JP2009541249A (en) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー Arylsulfonylnaphthalene derivatives and uses thereof
FR2913886B1 (en) 2007-03-22 2012-03-02 Guerbet Sa USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE
JP2011519839A (en) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ Modulator of dopamine neurotransmission
MX2010011498A (en) 2008-04-29 2010-11-12 Nsab Af Neurosearch Sweden Ab Modulators of dopamine neurotransmission.
WO2009133107A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
CN114890978B (en) * 2022-04-19 2023-07-25 宿迁医美科技有限公司 Phenolic compound, and preparation method and application thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (en) * 1988-07-28 1990-02-01 Bayer Ag SUBSTITUTED AMINOMETHYLZETRALINE AND ITS HETEROCYCLIC ANALOG
TW224941B (en) * 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
US5506192A (en) * 1990-06-07 1996-04-09 Sandoz Ltd. Substituted phthalides and heterocyclic phthalides
EP0541807B1 (en) * 1990-07-27 1997-12-17 Chugai Seiyaku Kabushiki Kaisha Novel benzopyran derivative
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5817693A (en) * 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
ZA93436B (en) * 1992-01-24 1993-08-25 Chugai Pharmaceutical Co Ltd Benzopyran derivatives
DE69328366T2 (en) * 1992-08-17 2000-08-10 Chugai Pharmaceutical Co Ltd BENZOPYRANE AND BENZOXAZINE DERIVATIVES
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
GB9309716D0 (en) * 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5869478A (en) 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
PL324319A1 (en) 1995-06-30 1998-05-25 Upjohn Co 1,6-disubstituted isochromates for fighting against sick headaches
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
JP2001501918A (en) 1996-08-21 2001-02-13 スミスクライン・ビーチャム・コーポレイション IL-8 receptor antagonist
US6559144B2 (en) * 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
US6310107B1 (en) * 1997-02-27 2001-10-30 Takeda Chemical Industries, Ltd. Amine compounds, their production and use as amyloid-β production inhibitors
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
FR2778662B1 (en) * 1998-05-12 2000-06-16 Adir NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE261435T1 (en) * 1998-12-04 2004-03-15 Takeda Chemical Industries Ltd BENZOFURAN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
WO2001074756A1 (en) * 2000-04-03 2001-10-11 Takeda Chemical Industries, Ltd. Process for producing amine derivatives
AR035858A1 (en) * 2001-04-23 2004-07-21 Bayer Corp CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS
MXPA04003087A (en) * 2001-10-04 2004-09-06 Wyeth Corp Chroman derivatives as 5-hydroxytryptamine-6 ligands.
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
PL211057B1 (en) * 2002-05-13 2012-04-30 Hoffmann La Roche Benzoxazine derivatives as 5-ht6 modulators and uses thereof
JP4754821B2 (en) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders
US7795242B2 (en) * 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
CA2542064A1 (en) 2003-10-24 2005-05-06 Exelixis, Inc. Tao kinase modulators and methods of use

Also Published As

Publication number Publication date
RU2006138180A (en) 2008-06-10
EP1748995A1 (en) 2007-02-07
KR20070009664A (en) 2007-01-18
TW200605894A (en) 2006-02-16
ZA200608588B (en) 2008-06-25
BRPI0510642A (en) 2007-11-20
IL178819A0 (en) 2007-03-08
NZ550441A (en) 2009-07-31
AR048936A1 (en) 2006-06-14
CA2566196A1 (en) 2005-11-10
ATE458727T1 (en) 2010-03-15
KR100823805B1 (en) 2008-04-21
TWI298636B (en) 2008-07-11
US7368567B2 (en) 2008-05-06
NO20065510L (en) 2007-01-12
WO2005105776A1 (en) 2005-11-10
HK1104533A1 (en) 2008-01-18
JP2007536302A (en) 2007-12-13
CN1960983A (en) 2007-05-09
CN100540546C (en) 2009-09-16
DE602005019562D1 (en) 2010-04-08
ES2338668T3 (en) 2010-05-11
AU2005238179A1 (en) 2005-11-10
EP1748995B1 (en) 2010-02-24
MXPA06012621A (en) 2006-12-15
AU2005238179B2 (en) 2010-08-26
RU2372344C2 (en) 2009-11-10
US20050250943A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
WO2005105776A8 (en) Arylsulfonyl benzodioxanes useful for modulation the 5-ht6 receptor, the 5-ht2areceptor or both
MX2009011830A (en) Amino-heterocyclic compounds.
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
RS20060129A (en) /1,8/naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MY149422A (en) 5-(arylsulfonyl)-pyrazolopiperidines
MX2010005717A (en) Isoxazolo-pyridine derivatives.
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
TW200745135A (en) Therapeutic agents
WO2005111002A3 (en) Substituted cycloalkyl derivatives for use in the treatment of respiratory diseases
JO2372B1 (en) Prodrugs of 4-phenyl-pyridine derivatives
MX2007005189A (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists.
CY1119787T1 (en) Substituted 2- [2- (phenyl) ethylamino] alkanamide derivatives and their use as sodium and / or lactate modifiers
NO20073051L (en) Tetralin and indan derivatives and their use
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
WO2007143523A8 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
MX2009014001A (en) Isoxazole-imidazole derivatives.
IN266803B (en)
TW200635589A (en) Therapeutic agents
RS50578B (en) Substituted 2-aminotetralines for the preventive treatment of parkinsons desease
TW200740781A (en) Novel compounds
TW200716547A (en) Piperidin-4-yl-amide derivatives
MX2009004898A (en) Indole and benzofuran 2-carboxamide derivatives.
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005734404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 550441

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006/08588

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 12006502067

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2005238179

Country of ref document: AU

Ref document number: 178819

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 06109665

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012621

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2566196

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067023073

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 4062/CHENP/2006

Country of ref document: IN

Ref document number: 200580014368.2

Country of ref document: CN

Ref document number: 2007511952

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005238179

Country of ref document: AU

Date of ref document: 20050427

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005238179

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006138180

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020067023073

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005734404

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0510642

Country of ref document: BR